Cidara Therapeutics Inc
NASDAQ:CDTX
Cidara Therapeutics Inc
Revenue
Cidara Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cidara Therapeutics Inc
NASDAQ:CDTX
|
Revenue
$63.9m
|
CAGR 3-Years
74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Cidara Therapeutics Inc's Revenue?
Revenue
63.9m
USD
Based on the financial report for Dec 31, 2023, Cidara Therapeutics Inc's Revenue amounts to 63.9m USD.
What is Cidara Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
74%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Cidara Therapeutics Inc have been 74% over the past three years .